Haematological changes during intermittent treatment with rifampicin.
D000917:Antibody Formation; D001772:Blood Cell Count; D001792:Blood Platelets; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D004417:Dyspnea / Q000139:chemically induced; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D007136:Immunoglobulins; D004977:Ethambutol; D011241:Prednisone; D012293:Rifampin